TripSitter Clinic Ltd.
TSTTF
Other OTC0.02
USD
- -
- -
ISIN
CA89680B2049
CUSIP
89680B204
Return %
Stock
S&P500
1Y
630.00
26.53
3Y
-74.24
76.60
5Y
-95.71
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- John Huber
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 77 King Street West Toronto ON Canada M5K 1G8
- IPO Date
- May 4, 2022
- Website
- tripsitter.clinic
- Similar Companies
- Business
- TripSitter Clinic Ltd. (CSE: KETA, OTC: TSTTF) operates a SaaS-based telehealth platform specializing in virtual psychedelic-assisted therapy for mental health conditions, including depression, anxiety, post-traumatic stress disorder, bipolar disorder, and obsessive-compulsive disorder; its core offerings encompass consultative virtual clinic services, patient monitoring, therapeutic coaching, care coordination, and connections to licensed U.S. physicians for prescribed low-dose ketamine treatment programs, requiring primary care physician diagnoses for intake. The company facilitates remote psychotherapy combined with psychedelic treatments, operating through its wholly-owned subsidiary TripSitter Clinic Corp., with services primarily targeted at U.S. patients via a mobile-first web application. Founded in 2021 and headquartered in Toronto, Ontario, Canada, with additional operational presence noted in Vancouver, British Columbia, TripSitter focuses on the intersection of telemedicine and emerging psychedelic medicine sectors. In recent developments, TripSitter completed the acquisition of core assets from Insight Systems PBC, doing business as Reconscious Medical, in early 2023, enhancing its capabilities in psychedelic psychotherapy with both in-clinic and virtual care protocols for high- and low-dose ketamine integration. The transaction, effective from late 2022 agreements, included settlement of approximately US$76,000 in debt and led to executive changes, such as the appointment of Dr. Mark Braunstein as a key leader and shifts in CFO and director roles. As of late 2024 filings, the company reports no active business operations following subsidiary dissolutions and restructuring, while maintaining its platform infrastructure.